{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:53:23Z","timestamp":1789502003843,"version":"build-2803163510"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Busulfan (Bu) is an alkylating agent used as part of the conditioning regimen in pediatric patients before hematopoietic stem cell transplantation. Despite intravenous (IV) administration and dosing recommendations based on age and weight, reports have revealed interindividual variability in Bu pharmacokinetics and the outcomes of hematopoietic stem cell transplantation. In this context, adjusting doses to Bu's narrow therapeutic window is advised. We aimed to assess the utility of therapeutic drug monitoring (TDM) of Bu in children, the reliability of Bu quantification methods, and its stability in plasma when stored for up to 5 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Eighteen patients from our TDM center (252 samples) were included. All of them received a 2-hour Bu IV infusion 4 times daily for a total of 16 doses. The first dose of Bu was age\/weight-based, and the subsequent doses were adjusted from third or fifth dose onward based on the estimated first dose pharmacokinetic parameters to target steady-state concentrations (Css) of 600\u2013900 ng\/mL. The performance of our unit's high-performance liquid chromatography with tandem mass spectrometry method was assessed using a quality control (QC, 35 series) chart. International, multicenter, cross-validation test (n = 21) was conducted to validate different analytical methods. To assess Bu stability, regression analyses and Bland\u2013Altman plots were performed on measurements at repeated time points on samples stored at \u221280\u00b0C for up to 5 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>We observed a 4.2-fold interindividual variability in Bu Css after the first dose, with only 28% of children having a Css within the target range. During the 4 days of conditioning, 83% of children had their doses modified according to TDM recommendations. This achieved a Css within the target range in 75% of the children. Routine QC measurements were generally within the \u00b115% range around theoretical values, showing the optimal robustness of our center's analytical method. Two of the 21 Bu TDM centers returned inadequate results during cross-validation testing; both used a UV detection method. Storage at \u221280\u00b0C led to a fall in Bu content of 14.9% \u00b1 13.4% at 2\u20134 years and of 20% \u00b1 5% by 5 years (r<jats:sup>2<\/jats:sup><jats:sub>overall<\/jats:sub>= 0.92).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>We conclude that TDM is an effective method of achieving targeted Bu levels in children. QC programs are crucial to monitoring and maintaining the quality of an analytical method.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000468","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T20:45:50Z","timestamp":1510951550000},"page":"84-92","source":"Crossref","is-referenced-by-count":28,"title":["Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance"],"prefix":"10.1097","volume":"40","author":[{"given":"Choong","family":"Eva","sequence":"first","affiliation":[{"name":"CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland;"},{"name":"Onco-Hematology Unit, Department of Pediatrics, Geneva University Hospitals, University of Geneva, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uppugunduri","family":"Chakradhara Rao Satyanarayana","sequence":"additional","affiliation":[{"name":"CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland;"},{"name":"Onco-Hematology Unit, Department of Pediatrics, Geneva University Hospitals, University of Geneva, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Denis","sequence":"additional","affiliation":[{"name":"CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland;"},{"name":"Onco-Hematology Unit, Department of Pediatrics, Geneva University Hospitals, University of Geneva, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuntzinger","family":"Melanie","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Geneva University Hospitals, University of Geneva, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doffey-Lazeyras","family":"Fabienne","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Toxicology Unit, Geneva University Hospitals, University of Geneva, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo Piccolo","family":"Rodolfo","sequence":"additional","affiliation":[{"name":"Onco-Hematology Unit, Department of Pediatrics, Geneva University Hospitals, University of Geneva, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalandon","family":"Yves","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medical Specialties, Geneva University Hospitals, Geneva, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peters","family":"Christina","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation Unit, Department of Pediatrics, St. Anna Children's Hospital, Vienna, Austria. P. Christina is now with on behalf of ALL SCTped Forum group (NCT01949129) and on behalf of Pediatric Diseases Working Party of European Society for Blood Marrow Transplantation (PDWP-EBMT)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daali","family":"Youssef","sequence":"additional","affiliation":[{"name":"CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland;"},{"name":"Clinical Pharmacology and Toxicology Unit, Geneva University Hospitals, University of Geneva, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansari","family":"Marc","sequence":"additional","affiliation":[{"name":"CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland;"},{"name":"Onco-Hematology Unit, Department of Pediatrics, Geneva University Hospitals, University of Geneva, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/bmt.2008.54","article-title":"Endocrinological late complications after hematopoietic SCT in children","volume":"41","author":"Cohen","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ijrobp.2005.04.031","article-title":"Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant","volume":"63","author":"Faraci","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"R3-20230814","first-page":"S18","article-title":"Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens","volume":"20","author":"Grochow","year":"1993","journal-title":"Semin Oncol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/bmt.2015.218","article-title":"Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children","volume":"51","author":"Philippe","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2008.11.022","article-title":"Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation","volume":"15","author":"Bartelink","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0091270006295789","article-title":"Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients","volume":"47","author":"Booth","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2125.2002.01555.x","article-title":"Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation","volume":"53","author":"Cremers","year":"2002","journal-title":"Br J Clin Pharmacol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2004.07.010","article-title":"Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation","volume":"10","author":"Tran","year":"2004","journal-title":"Biol Blood Marrow Transplant."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00280-007-0455-2","article-title":"Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring","volume":"61","author":"Vassal","year":"2008","journal-title":"Cancer Chemother Pharmacol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.bbmt.2015.05.006","article-title":"Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning","volume":"21","author":"Zao","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1700994","article-title":"High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients","volume":"20","author":"Ljungman","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/1389200215666140202214012","article-title":"Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children","volume":"15","author":"Huezo-Diaz","year":"2014","journal-title":"Curr Drug Metab."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1399-3046.2011.01529.x","article-title":"Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients","volume":"15","author":"Malar","year":"2011","journal-title":"Pediatr Transplant."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1702371","article-title":"An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease","volume":"25","author":"Bolinger","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based bonditioning: bonsiderations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/FTD.0b013e3182a04fc7","article-title":"Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation","volume":"36","author":"Ansari","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FTD.0000000000000131","article-title":"Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use","volume":"37","author":"Long-Boyle","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","article-title":"Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing","volume":"51","author":"Bartelink","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/sj.bmt.1703207","article-title":"Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens","volume":"28","author":"Bleyzac","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/petr.12430","article-title":"Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation","volume":"19","author":"Gurlek Gokcebay","year":"2015","journal-title":"Pediatr Transplant."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/FTD.0b013e3181a8c99c","article-title":"Determination of busulfan in human plasma using an ELISA format","volume":"31","author":"Courtney","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/FTD.0b013e318214cd75","article-title":"An automated method for supporting busulfan therapeutic drug monitoring","volume":"33","author":"Juenke","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0378-4347(98)00473-3","article-title":"High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol","volume":"721","author":"Quernin","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00685617","article-title":"Gas-chromatographic analysis of busulfan for therapeutic drug monitoring","volume":"32","author":"Embree","year":"1993","journal-title":"Cancer Chemother Pharmacol."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-1-60761-459-3_12","article-title":"Quantification of busulfan in plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESI-MS\/MS)","volume":"603","author":"Snyder","year":"2010","journal-title":"Methods Mol Biol."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.ftd.0000173372.04945.7b","article-title":"Tandem mass spectrometry method for the quantification of serum busulfan","volume":"27","author":"Kellogg","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/rcm.6241","article-title":"A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography\/tandem mass spectrometry","volume":"26","author":"Ansari","year":"2012","journal-title":"Rapid Commun Mass Spectrom."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/clinchem\/47.4.766","article-title":"Stability of busulfan in frozen plasma and whole blood samples","volume":"47","author":"Balasubramanian","year":"2001","journal-title":"Clin Chem."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","article-title":"Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization","volume":"20","author":"McCune","year":"2014","journal-title":"Clin Cancer Res."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood."},{"key":"R32-20230814","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0016-5085(98)70361-0","article-title":"Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial","volume":"115","author":"McDonald","year":"1998","journal-title":"Gastroenterology."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/bmt.2009.143","article-title":"Influence of GST gene polymorphisms on busulfan pharmacokinetics in children","volume":"45","author":"Ansari","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bmt.2012.265","article-title":"Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients","volume":"48","author":"Ansari","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0091270012447196","article-title":"Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients","volume":"53","author":"McCune","year":"2013","journal-title":"J Clin Pharmacol."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.bbmt.2017.07.022","article-title":"GSTA1 genetic variants and conditioning regimen: missing key factors in dosing guidelines of busulfan in pediatric hematopoietic stem cell transplantation","volume":"23","author":"Nava","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2006.10.026","article-title":"Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Schechter","year":"2007","journal-title":"Biol Blood Marrow Transplant."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/sj.bmt.1704209","article-title":"Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results","volume":"32","author":"Dalle","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bbmt.2010.12.708","article-title":"Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/pbc.22739","article-title":"Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation","volume":"55","author":"Elhasid","year":"2010","journal-title":"Pediatr Blood Cancer."},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2013.08.014","article-title":"Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation","volume":"19","author":"Savic","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FTD.0b013e31824c2f60","article-title":"Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation","volume":"34","author":"Paci","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","article-title":"Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality","volume":"13","author":"McCune","year":"2007","journal-title":"Biol Blood Marrow Transplant."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood."},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","article-title":"The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity","volume":"25","author":"Hassan","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"R50-20230814","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.4155\/bio.10.142","article-title":"Utility of dried blood spot sampling and storage for increased stability of photosensitive compounds","volume":"2","author":"Bowen","year":"2010","journal-title":"Bioanalysis."},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.4155\/bio.11.76","article-title":"Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research","volume":"3","author":"Yadav","year":"2011","journal-title":"Bioanalysis."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201802000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T19:26:05Z","timestamp":1719602765000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201802000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000468","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}